Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Institute Of Life Sciences has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit.
TRAN, ERIC is the listed examiner and has 1 pending matter. Counsel can focus on the single biotechnology record, using the pending claims and stated examination issues to guide the response.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, ERIC | 1 | 69.8% | +19.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18853042 | A PHARMACEUTICAL COMPOSITION COMPRISING AN INHIBITOR OF GLUTAMINE SYNTHETASE ENZYME TO COMBAT ARTEMISININ RESISTANCE IN MALARIA | TRAN, ERIC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18853042 | A PHARMACEUTICAL COMPOSITION COMPRISING AN INHIBITOR OF GLUTAMINE SYNTHETASE ENZYME TO COMBAT ARTEMISININ RESISTANCE IN MALARIA | TRAN, ERIC | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18853042 | A PHARMACEUTICAL COMPOSITION COMPRISING AN INHIBITOR OF GLUTAMINE SYNTHETASE ENZYME TO COMBAT ARTEMISININ RESISTANCE IN MALARIA | TRAN, ERIC | 1629 | §103§112 | Non-Final OA | — | Pending | Sep 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInstitute Of Life Sciences has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Eric Tran has the most, with 1 of Institute Of Life Sciences's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
